ID   CX-1
AC   CVCL_2011
SY   HT-29/CX-1; CX1
DR   BTO; BTO:0002440
DR   CLO; CLO_0002650
DR   EFO; EFO_0006561
DR   CLDB; cl939
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03473136
DR   ChEMBL-Cells; CHEMBL3307403
DR   ChEMBL-Targets; CHEMBL614566
DR   CLS; 300159/p496_CX-1
DR   ColonAtlas; CX1
DR   Cosmic; 948826
DR   Cosmic; 995389
DR   Cosmic; 1043809
DR   Cosmic; 1374637
DR   Cosmic; 2301971
DR   DSMZ; ACC-129
DR   GEO; GSM206466
DR   GEO; GSM274761
DR   GEO; GSM274762
DR   GEO; GSM1346835
DR   GEO; GSM1448120
DR   IARC_TP53; 4561
DR   PharmacoDB; CX1_270_2019
DR   Wikidata; Q54817065
RX   PubMed=10737795;
RX   PubMed=12601555;
RX   PubMed=16418264;
RX   PubMed=20606684;
RX   PubMed=24755471;
RX   PubMed=25485619;
RX   PubMed=25926053;
RX   PubMed=28196595;
WW   http://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: ~24 hours (CLS); ~30 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (PubMed=25926053).
CC   Sequence variation: Heterozygous for APC p.Glu853Ter (c.2557G>T) and p.Thr1556fs*3 (c.4666_4667insA) (from parent cell line).
CC   Sequence variation: Heterozygous for BRAF p.Val600Glu (c.1799T>A) (from parent cell line).
CC   Sequence variation: Heterozygous for PIK3CA p.Pro449Thr (c.1345C>A) (from parent cell line).
CC   Sequence variation: Homozygous for SMAD4 p.Gln311Ter (c.931C>T) (from parent cell line).
CC   Sequence variation: Homozygous for TP53 p.Arg273His (c.818G>A) (PubMed=16418264).
CC   Omics: Deep RNAseq analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
ST   Source(s): CLS; DSMZ; PubMed=25877200; PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 13
ST   D21S11: 29,30
ST   D3S1358: 15,17
ST   D5S818: 11,12
ST   D7S820: 10
ST   D8S1179: 10
ST   FGA: 20,22
ST   Penta D: 11,13
ST   Penta E: 14,16
ST   TH01: 6,9
ST   TPOX: 8,9
ST   vWA: 17,19
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0320 ! HT-29
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 22
//
RX   PubMed=10737795; DOI=10.1073/pnas.97.7.3352;
RA   Rowan A.J., Lamlum H., Ilyas M., Wheeler J., Straub J.,
RA   Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.;
RT   "APC mutations in sporadic colorectal tumors: a mutational 'hotspot'
RT   and interdependence of the 'two hits'.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).
//
RX   PubMed=12601555; DOI=10.1007/s100380300014;
RA   Ni X.-H., Gu S.-H., Dai J.-L., Cheng H.-P., Guo L.-C., Li L., Ji C.-N.,
RA   Xie Y., Ying K., Mao Y.-M.;
RT   "Isolation and characterization of a novel human NM23-H1B gene, a
RT   different transcript of NM23-H1.";
RL   J. Hum. Genet. 48:96-100(2003).
//
RX   PubMed=16418264; DOI=10.1073/pnas.0510146103;
RA   Liu Y., Bodmer W.F.;
RT   "Analysis of P53 mutations and their expression in 56 colorectal
RT   cancer cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
//
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002-7002(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//